Lenalidomide Glenmark

Lenalidomide, the active ingredient in Lenalidomide Glenmark, is an immunomodulatory agent (IMiD) presented as a tablet for oral use. It treats multiple myeloma and myelodysplastic syndromes with del(5q) in adult patients.

GNH USA supplies Lenalidomide Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic bone‑marrow clones. - Multiple Myeloma: improves progression‑free survival and overall response rates, especially in relapsed or refractory disease. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and improves peripheral blood counts. - Maintenance Therapy after Autologous Stem Cell Transplant in Multiple Myeloma: prolongs remission duration and delays disease progression.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels leading to bleeding tendencies. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may cause dehydration. - Constipation: difficulty passing stool. - Rash: mild skin eruptions.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary primary malignancies: emergence of new cancers. - Hepatic failure: significant liver enzyme elevation or dysfunction. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Lenalidomide requires careful monitoring and specific safety measures before and during therapy. - Pregnancy Contraindication: teratogenic; avoid use in pregnant women and ensure effective contraception. - Thrombosis Risk: assess for clotting risk and consider prophylactic anticoagulation when indicated. - Hematologic Monitoring: perform regular complete blood counts to detect neutropenia or thrombocytopenia. - Renal Impairment: adjust dose in patients with reduced kidney function. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lenalidomide can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Combined use with thalidomide: markedly increases risk of peripheral neuropathy and thromboembolic events. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce lenalidomide exposure and efficacy. - Anticoagulants (warfarin): heightened bleeding risk; monitor coagulation parameters closely.

Moderate Interactions (Monitor Closely): - NSAIDs (ibuprofen, naproxen): may exacerbate renal toxicity. - Antibiotics that inhibit renal transport (e.g., trimethoprim): could increase lenalidomide plasma levels. - Live vaccines: contraindicated due to immunosuppressive effects; avoid administration during treatment.